Mirati Ther is a biotechnology business based in the US. Mirati Ther shares (MRTX) are listed on the NASDAQ and all prices are listed in US Dollars. Mirati Ther employs 587 staff and has a trailing 12-month revenue of around $38.2 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $58.70 |
|---|---|
| 52-week range | $27.30 - $64.41 |
| 50-day moving average | $57.93 |
| 200-day moving average | $45.92 |
| Wall St. target price | $64.50 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-12.18 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $58.7 from 2024-01-23
| 1 week (2024-07-16) | N/A |
|---|---|
| 1 month (2024-06-23) | N/A |
| 3 months (2024-04-23) | N/A |
| 6 months (2024-01-23) | 58.7 |
| 1 year (2023-07-27) | 104.96% |
|---|---|
| 2 years (2022-07-27) | -13.70% |
| 3 years (2021-07-27) | 152.26 |
| 5 years (2019-07-26) | 98.65 |
| Revenue TTM | $38.2 million |
|---|---|
| Gross profit TTM | $-519,791,000 |
| Return on assets TTM | -39.3% |
| Return on equity TTM | -69.95% |
| Profit margin | 0% |
| Book value | $13.50 |
| Market Capitalization | $4.1 billion |
TTM: trailing 12 months
We're not expecting Mirati Ther to pay a dividend over the next 12 months.
Mirati Ther's shares were split on a 1:50 basis on 2 July 2013. So if you had owned 50 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Mirati Ther shares – just the quantity. However, indirectly, the new 4900% higher share price could have impacted the market appetite for Mirati Ther shares which in turn could have impacted Mirati Ther's share price.
Over the last 12 months, Mirati Ther's shares have ranged in value from as little as $27.3 up to $64.41. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Mirati Ther's is 0.77. This would suggest that Mirati Ther's shares are less volatile than average (for this exchange).
Mirati Therapeutics, Inc. , a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. The company provides KRAZATI, an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung (NSCLC), as well as in clinical development as a monotherapy and in combination with other agents. It also develops Sitravatinib, an investigational spectrum-selective kinase inhibitor in Phase 3 clinical development that inhibits receptor tyrosine kinases (RTKs), including TAM family receptors, split family receptors, and RET, which overcomes resistance to checkpoint inhibitor therapy through targeted reversal of an immunosuppressive tumor microenvironment that enhances antigen-specific T cell response and expanding dendritic cell-dependent antigen presentation. In addition, the company pipeline comprises the MRTX1719, an investigational synthetic lethal PRMT5 inhibitor designed to target the PRMT5/methylthioadensoine (MTA) complex and is in clinical development; MRTX0902, a selective SOS1 inhibitor that improves anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors, and is in clinical development; and MRTX1133, an investigational lead KRAS G12D compound. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and Zai Lab Ltd.
Learn these options trading strategies to lock in profits and get acquainted with a new asset class.
Trade commission-free stocks and ETFs with Opto, and stay ahead by spotting emerging trends through thematic investing.
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
Spot Ethereum ETFs might soon be approved. Here’s how to invest if and when they become available to trade.
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
Explore the best bonuses for opening a new brokerage account.
We’ve rounded up stats on some of the most popular semiconductor stocks, along with information on how they compare and how to invest.
Check out our picks of the best brokerage accounts for beginners, micro-investing, crypto trading and more.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out our 7 ideas for how to invest $10K to maximize your money.